Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11761304 | 0.88 | LMNA (0.60) | LMNATSHRMAPTALDH1A1HSD17B10 | |
| SCHEMBL10012267 | 0.83 | LMNA (0.42) | LMNATSHRMAPTHTTALDH1A1 | |
| SCHEMBL14037570 | 0.78 | LMNA (0.48) | LMNATSHRMAPTHTTALDH1A1 | |
| SCHEMBL72471 | 0.78 | LMNA (0.62) | LMNATSHRMAPTHTTALDH1A1 | |
| SCHEMBL1170737 | 0.77 | — | — | |
| SCHEMBL31402602 | 0.76 | LMNA (0.60) | LMNATSHRMAPTHTTALDH1A1 | |
| SCHEMBL6748118 | 0.76 | LMNA (0.41) | LMNATSHRMAPTALDH1A1KDM4E | |
| SCHEMBL10012660 | 0.75 | TSHR (0.40) | LMNATSHRACACBMEN1KMT2A | |
| SCHEMBL26454522 | 0.75 | TSHR (0.39) | LMNATSHRMAPTALDH1A1KDM4E | |
| SCHEMBL1050327 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458941-B | Use the manufacturing method of the isothiazole compounds of ether compound | 组合化学工业株式会社 | 2019-08-30 | — | — | CN | disclosed |
| EP-3333173-B1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2019-06-26 | — | — | EP | disclosed |
| EP-3127902-B1 | METHOD FOR PRODUCING ISOTHIAZOLE COMPOUND USING ETHER COMPOUND | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2018-11-07 | — | — | EP | disclosed |
| EP-3333173-A1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | Gilead Sciences, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-2764002-B1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9676804-B2 | Methods for preparing anti-viral nucleotide analogs | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170056423-A1 | COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-02 | — | — | US | disclosed |
| CN-106458941-A | Method for producing isothiazole compound using ether compound | 庵原化学工业株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-3127902-A1 | METHOD FOR PRODUCING ISOTHIAZOLE COMPOUND USING ETHER COMPOUND | Ihara Chemical Industry Co., Ltd. (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20160311840-A1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2013116730-A1 | COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20130090473-A1 | Methods for preparing anti-viral nucleotide analogs | GILEAD SCIENCES, INC. | 2013-04-11 | — | — | US | disclosed |
| WO-2013052094-A2 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20120053350-A1 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | MERCK SHARP & DOHME CORP. | 2012-03-01 | — | — | US | disclosed |
| WO-2010126820-A2 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-1626950-A4 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS INC (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7186863-B2 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1626950-A1 | SERTRALINE COMPOSITIONS | Transform Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050014829-A1 | Sertraline compositions | TRANSFORM PHARMACEUTICALS, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2005000786-A1 | SERTRALINE COMPOSITIONS | TRANSFORM PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014829-A1 | Sertraline compositions | SUCNR1, TST, SORD | LMNA 2403/4885TSHR 96/4885MAPT 294/4885 |
| US-20160311840-A1 | METHODS FOR PREPARING ANTI-VIRAL NUCLEOTIDE ANALOGS | MTAP, PNP, ADAR | LMNA 312/4885TSHR 4721/4885MAPT 4594/4885 |
| US-20120053350-A1 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | SULT1A1, SULT1E1, PGD | LMNA 1743/4885TSHR 3444/4885MAPT 4875/4885 |
| US-20130090473-A1 | Methods for preparing anti-viral nucleotide analogs | MTAP, ADAR, PNP | LMNA 323/4885TSHR 4671/4885MAPT 4640/4885 |
| US-20170056423-A1 | COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | MTAP, PAICS, GART | LMNA 3262/4885TSHR 4483/4885MAPT 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.